JOHNSON & JOHNSON is 241.8x more valuable than Ultragenyx Pharmaceutical Inc. by market capitalization ($579.83 B vs $2.40 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | RARE | JNJ |
|---|---|---|
| Market cap | $2.40 B | $579.83 B |
| US-listed rank | #1989 | #20 |
| Revenue (latest FY) | $673.00M | $94.19B |
| Net income (latest FY) | -$575.00M | $26.80B |
| Net margin | -85.4% | 28.5% |
| P/E (trailing FY) | - | 21.6 |
| SEC filings | 1,100 | 984 |
JOHNSON & JOHNSON is 241.8x more valuable than Ultragenyx Pharmaceutical Inc. by market capitalization ($579.83 B vs $2.40 B).
In their latest fiscal years, Ultragenyx Pharmaceutical Inc. reported $673.00M in revenue while JOHNSON & JOHNSON reported $94.19B.
Full pages: Ultragenyx Pharmaceutical Inc. and JOHNSON & JOHNSON, or browse the full rankings.